Abstract:Mitochondria share extensive evolutionary conservation across nearly all living species. This homology allows robust insights to be gained into pathophysiologic mechanisms and therapeutic targets for the heterogeneous class of primary mitochondrial diseases through the study of diverse in vitro cellular and in vivo animal models. Dramatic advances in genetic technologies, ranging from RNA interference to achieve graded knock‐down of gene expression to CRISPR/Cas‐based gene editing that yields a stable gene knock‐out or targeted mutation knock‐in, have enabled the ready establishment of mitochondrial disease models for a plethora of individual nuclear gene disorders. These models are complemented and extended by the use of pharmacologic inhibitor‐based stressors to characterize variable degrees, onset, duration, and combinations of acute on chronic mitochondrial dysfunction in individual respiratory chain enzyme complexes or distinct biochemical pathways in mitochondria. Herein is described the rationale for, and progress made in, "therapeutic cross‐training", a novel approach meant to improve the validity and rigor of experimental conclusions when testing therapies by studying treatment effects in multiple, evolutionarily‐distinct species, including C. elegans (invertebrate, worm), D. rerio (vertebrate, zebrafish), M. musculus (mammal, mouse), and/or human patient primary fibroblast cell line models of primary mitochondrial disease. The goal of these pre‐clinical studies is to identify lead therapies from candidate molecules or library screens that consistently demonstrate efficacy, with minimal toxicity, in specific subtypes of mitochondrial disease. Conservation of in vitro and in vivo therapeutic effects of lead molecules across species has proven extensive, where molar concentrations found to be toxic or efficacious in one species are often consistent with therapeutic effects at similar doses seen in other mitochondrial disease models. Phenotypic outcome studies in all models are prioritized at the level of survival and function, to reflect the ultimate goal of developing highly potent therapies for human mitochondrial disease. Lead compounds that demonstrate significant benefit on gross phenotypes may be further scrutinized in these same models to decipher their cellular targets, mechanism(s), and detailed biochemical effects. High‐throughput, automated technologic advances will be discussed that enable efficient, parallel screening in a diverse mitochondrial disease disorders and overarching subclasses of compounds, concentrations, libraries, and combinations. Overall, this therapeutic cross‐training approach has proven valuable to identify compounds with optimal potency and safety profiles among major biochemical subtypes or specific genetic etiologies of mitochondrial disease. This approach further supports rational prioritization of lead compounds, target concentrations, and specific disease phenotypes, outcomes, and subgroups to optimally inform the design of clinical trials that test their efficacy in human mitochondrial disease subjects.

An evolving roadmap: using mitochondrial physiology to help guide conservation efforts

Conservation Mitonuclear Replacement: Facilitated mitochondrial adaptation for a changing world

Mitochondria: It is all about energy

Reframing conservation physiology to be more inclusive, integrative, relevant and forward-looking: reflections and a horizon scan

Incorporating otolith-isotope inferred field metabolic rate into conservation strategies

Navigating the landscape of mitochondrial-ER communication in health and disease

The Key Role of Mitochondrial Function in Health and Disease

From OCR and ECAR to energy: Perspectives on the design and interpretation of bioenergetics studies

Advancing bioenergetics-based modeling to improve climate change projections of marine ecosystems

Ectotherm mitochondrial economy and responses to global warming

Revolutionizing cellular energy: The convergence of mitochondrial dynamics and delivery technologies

The pursuit of precision mitochondrial medicine: Harnessing preclinical cellular and animal models to optimize mitochondrial disease therapeutic discovery

Mechanisms of mitochondrial respiratory adaptation

The Earliest Stages of Mitochondrial Adaptation to Low Oxygen Revealed in a Novel Rhizarian

From chronology to the biology of aging, and its tuning by mitochondrial health: overview of the Bioenergetics, Mitochondria, and Metabolism subgroup symposium at the 2021 Virtual 65th Annual Meeting of the Biophysical Society

Targeting organ-specific mitochondrial dysfunction to improve biological aging

A Mitochondrial Perspective on the Demands of Reproduction

Mitochondria as central characters in a complex narrative: Linking genomics, energetics, pace-of-life, and aging in natural populations of garter snakes

Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction

Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism

Harnessing Mitochondrial Function in Human Diseases Using New Marine-Derived Strategies